FIGHT-207 is a multi-centre international study to evaluate the efficacy and safety of pemigatinib in participants with activating FGFR mutations or translocations.
Full title: Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
This study is currently open at two centres in the UK:
- Sarah Cannon Institute, London – Dr Tobias Arkenau
- University College Hospital, London – Professor John Bridgewater
More details of the study can be found here:
https://bepartofresearch.nihr.ac.uk/ and search for Study: FIGHT-207
Incyte: https://www.incyte.comBack to previous page